In the last trading session, 1.9 million ITeos Therapeutics Inc (NASDAQ:ITOS) shares changed hands as the company’s beta touched 1.39. With the company’s per share price at $8.41 changed hands at $0.6 or 7.68% during last session, the market valuation stood at $321.88M. ITOS’s last price was a discount, traded about -122.35% off its 52-week high of $18.70. The share price had its 52-week low at $4.80, which suggests the last value was 42.93% up since then.
Analysts gave the ITeos Therapeutics Inc (ITOS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITOS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ITeos Therapeutics Inc’s EPS for the current quarter is expected to be -0.78.
ITeos Therapeutics Inc (NASDAQ:ITOS) trade information
Instantly ITOS was in green as seen at the end of in last trading. With action 21.53%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 9.51%, with the 5-day performance at 21.53% in the green. However, in the 30-day time frame, ITeos Therapeutics Inc (NASDAQ:ITOS) is 29.19% up.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 29.92% from its current market value. According to analyst projections, ITOS’s forecast low is 9 with 13 as the target high. To hit the forecast high, the stock’s price needs a -54.58% plunge from its current level, while the stock would need to soar -7.02% for it to hit the projected low.
ITeos Therapeutics Inc (ITOS) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 35M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.39%. The 2025 estimates are for ITeos Therapeutics Inc earnings to increase by 12.53%, but the outlook for the next 5-year period is at 3.89% per year.
ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 8.8598% or 3.52 million shares worth $52.2 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 855.64 shares estimated at $7.2 million under it, the former controlled 2.24% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.88% of the shares, roughly 719.67 shares worth around $6.05 million.
